



NEWS RELEASE

Arcus Biosciences to Present at the 9th Annual SVB Leerink Global Healthcare Conference

2/12/2020

HAYWARD, Calif.--(BUSINESS WIRE)-- Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that management will present at the 9th Annual SVB Leerink Global Healthcare Conference on Wednesday, February 26, 2020 at 9:30 a.m. Eastern Time in New York, NY.

A live audio webcast of the presentation will be available by visiting the "Investors" section of the Arcus website at www.arcusbio.com. A replay of the webcast will be available for at least 30 days following the live event.

About Arcus Biosciences

Arcus Biosciences is an oncology-focused biopharmaceutical company leveraging its deep cross-disciplinary expertise to discover highly-differentiated therapies and to develop a broad portfolio of novel combinations addressing significant unmet needs. **AB928**, the first and only dual adenosine A2a/A2b receptor antagonist in the clinic, is being evaluated in several Phase 1b/2 studies across multiple indications, including prostate, colorectal, non-small cell lung, pancreatic, triple negative breast and renal cell cancers. **AB680**, the first CD73 small-molecule inhibitor in the clinic, is in Phase 1/1b development for the treatment of first-line metastatic pancreatic cancer. **AB154**, an anti-TIGIT monoclonal antibody, is in Phase 2 development for the treatment of first-line metastatic non-small cell lung cancer in combination with zimberelimab and AB928. Zimberelimab (**AB122**), Arcus's anti-PD1 monoclonal antibody, is being evaluated in a Phase 1b study as monotherapy for cancers with no approved anti-PD1 treatment options, as well as in combinations across the portfolio. For more information about Arcus Biosciences, please visit www.arcusbio.com.

Source: Arcus Biosciences

View source version on **businesswire.com**: <https://www.businesswire.com/news/home/20200212005818/en/>

Katherine Bock

(510) 694-6231

kbock@arcusbio.com

Source: Arcus Biosciences, Inc.